{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-23-005571","form_type":"8-K","ticker":"PASG","cik":"0001787297","company_name":"Passage BIO, Inc.","filed_at":"2023-04-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.578283+00:00","generated_at":"2026-06-17T05:16:19.639363+00:00","sec_items":["1.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Passage Bio amends Catalent agreements, eliminates $10.6M annual minimum purchase obligation","bullets":["Eliminated $10.6M/year minimum purchase obligation and Clean Room Suite fee through Nov 2025.","Company to pay Catalent $6.0M total between June 2023 and May 2024 in consideration.","Extended term to Nov 6, 2030; limited exclusive relationship for AAV product candidates for FTD and GM1.","Exclusive relationship may convert to non-exclusive if Catalent fails performance standards or upon certain divestiture events.","Company may terminate for convenience in certain transactions, subject to termination fee."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-23-005571","json":"https://secwatch.observer/filing/0001558370-23-005571.json","markdown":"https://secwatch.observer/filing/0001558370-23-005571.md","text":"https://secwatch.observer/filing/0001558370-23-005571.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1787297/000155837023005571/0001558370-23-005571-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1787297/000155837023005571/pasg-20230331x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T05:16:19.639363+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"138dd18e0706915a7a89cf2592bd325951bb2ab9","claim":"Passage BIO, Inc. amended Letter Agreement II with Catalent Maryland, Inc. valued at $6.0 million (effective 2023-03-31).","evidence_excerpt":"Letter agreement II (“ Agreement II ” and together with Agreement I, the “Letter Agreements” ) extended the term of the Existing Agreements until November 6, 2030, and established a limited exclusive relationship between the Company and Catalent for the manufacture of bulk drug substance and drug product for the Company’s adeno-associated virus delivery therapeutic product candidates for the treatment of frontotemporal dementia and GM1 gangliosidosis (the “ Product Candidates ”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1787297/000155837023005571/0001558370-23-005571-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"amendment"},{"label":"Agreement","value":"supply"},{"label":"Counterparty","value":"Catalent Maryland, Inc."},{"label":"Value","value":"$6.0 million"},{"label":"Effective","value":"2023-03-31"}],"fact_type":"material_agreement"},{"claim_id":"41a2ea8f563389850d514c0c0b62b37841a4718d","claim":"Passage BIO, Inc. amended Letter Agreement I with Catalent Maryland, Inc. valued at $10.6 million per year (effective 2023-03-31).","evidence_excerpt":"Letter agreement I (“ Agreement I ”) eliminated the minimum annual purchase obligation and the obligation to pay an annual fee for use of the Clean Room Suite, thereby eliminating the annual minimum commitment of $10.6 million per year owed to Catalent through November 2025 under the Existing Agreements.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1787297/000155837023005571/0001558370-23-005571-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"amendment"},{"label":"Agreement","value":"license"},{"label":"Counterparty","value":"Catalent Maryland, Inc."},{"label":"Value","value":"$10.6 million per year"},{"label":"Effective","value":"2023-03-31"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}